Cargando…

Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis

Background and Objectives: To assess the effects of fosfomycin compared with other antibiotics as a prophylaxis for urinary tract infections (UTIs) in men undergoing transrectal prostate biopsies. Materials and Methods: We searched multiple databases and trial registries without publication language...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Hui Mo, Gu, Jin Seok, Chung, Ho Seok, Jung, Seung Il, Kwon, Dongdeuk, Kim, Myung Ha, Jung, Jae Hung, Han, Mi Ah, Kang, Seung Ji, Hwang, Eu Chang, Dahm, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221023/
https://www.ncbi.nlm.nih.gov/pubmed/37241143
http://dx.doi.org/10.3390/medicina59050911
_version_ 1785049357459914752
author Gu, Hui Mo
Gu, Jin Seok
Chung, Ho Seok
Jung, Seung Il
Kwon, Dongdeuk
Kim, Myung Ha
Jung, Jae Hung
Han, Mi Ah
Kang, Seung Ji
Hwang, Eu Chang
Dahm, Philipp
author_facet Gu, Hui Mo
Gu, Jin Seok
Chung, Ho Seok
Jung, Seung Il
Kwon, Dongdeuk
Kim, Myung Ha
Jung, Jae Hung
Han, Mi Ah
Kang, Seung Ji
Hwang, Eu Chang
Dahm, Philipp
author_sort Gu, Hui Mo
collection PubMed
description Background and Objectives: To assess the effects of fosfomycin compared with other antibiotics as a prophylaxis for urinary tract infections (UTIs) in men undergoing transrectal prostate biopsies. Materials and Methods: We searched multiple databases and trial registries without publication language or status restrictions until 4 January 2022. Parallel-group randomized controlled trials (RCTs) and non-randomized studies (NRS) were included. The primary outcomes were febrile UTI, afebrile UTI, and overall UTI. We used GRADE guidance to rate the certainty of evidence of RCTs and NRSs. The protocol was registered with PROSPERO (CRD42022302743). Results: We found data on five comparisons; however, this abstract focuses on the primary outcomes of the two most clinically relevant comparisons. Regarding fosfomycin versus fluoroquinolone, five RCTs and four NRSs with a one-month follow-up were included. Based on the RCT evidence, fosfomycin likely resulted in little to no difference in febrile UTIs compared with fluoroquinolone. This difference corresponded to four fewer febrile UTIs per 1000 patients. Fosfomycin likely resulted in little to no difference in afebrile UTIs compared with fluoroquinolone. This difference corresponded to 29 fewer afebrile UTIs per 1000 patients. Fosfomycin likely resulted in little to no difference in overall UTIs compared with fluoroquinolone. This difference corresponded to 35 fewer overall UTIs per 1000 patients. Regarding fosfomycin and fluoroquinolone combined versus fluoroquinolone, two NRSs with a one- to three-month follow-up were included. Based on the NRS evidence, fosfomycin and fluoroquinolone combined may result in little to no difference in febrile UTIs compared with fluoroquinolone. This difference corresponded to 16 fewer febrile UTIs per 1000 patients. Conclusions: Compared with fluoroquinolone, fosfomycin or fosfomycin and fluoroquinolone combined may have a similar prophylactic effect on UTIs after a transrectal prostate biopsy. Given the increasing fluoroquinolone resistance and its ease to use, fosfomycin may be a good option for antibiotic prophylaxis.
format Online
Article
Text
id pubmed-10221023
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102210232023-05-28 Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis Gu, Hui Mo Gu, Jin Seok Chung, Ho Seok Jung, Seung Il Kwon, Dongdeuk Kim, Myung Ha Jung, Jae Hung Han, Mi Ah Kang, Seung Ji Hwang, Eu Chang Dahm, Philipp Medicina (Kaunas) Systematic Review Background and Objectives: To assess the effects of fosfomycin compared with other antibiotics as a prophylaxis for urinary tract infections (UTIs) in men undergoing transrectal prostate biopsies. Materials and Methods: We searched multiple databases and trial registries without publication language or status restrictions until 4 January 2022. Parallel-group randomized controlled trials (RCTs) and non-randomized studies (NRS) were included. The primary outcomes were febrile UTI, afebrile UTI, and overall UTI. We used GRADE guidance to rate the certainty of evidence of RCTs and NRSs. The protocol was registered with PROSPERO (CRD42022302743). Results: We found data on five comparisons; however, this abstract focuses on the primary outcomes of the two most clinically relevant comparisons. Regarding fosfomycin versus fluoroquinolone, five RCTs and four NRSs with a one-month follow-up were included. Based on the RCT evidence, fosfomycin likely resulted in little to no difference in febrile UTIs compared with fluoroquinolone. This difference corresponded to four fewer febrile UTIs per 1000 patients. Fosfomycin likely resulted in little to no difference in afebrile UTIs compared with fluoroquinolone. This difference corresponded to 29 fewer afebrile UTIs per 1000 patients. Fosfomycin likely resulted in little to no difference in overall UTIs compared with fluoroquinolone. This difference corresponded to 35 fewer overall UTIs per 1000 patients. Regarding fosfomycin and fluoroquinolone combined versus fluoroquinolone, two NRSs with a one- to three-month follow-up were included. Based on the NRS evidence, fosfomycin and fluoroquinolone combined may result in little to no difference in febrile UTIs compared with fluoroquinolone. This difference corresponded to 16 fewer febrile UTIs per 1000 patients. Conclusions: Compared with fluoroquinolone, fosfomycin or fosfomycin and fluoroquinolone combined may have a similar prophylactic effect on UTIs after a transrectal prostate biopsy. Given the increasing fluoroquinolone resistance and its ease to use, fosfomycin may be a good option for antibiotic prophylaxis. MDPI 2023-05-10 /pmc/articles/PMC10221023/ /pubmed/37241143 http://dx.doi.org/10.3390/medicina59050911 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Gu, Hui Mo
Gu, Jin Seok
Chung, Ho Seok
Jung, Seung Il
Kwon, Dongdeuk
Kim, Myung Ha
Jung, Jae Hung
Han, Mi Ah
Kang, Seung Ji
Hwang, Eu Chang
Dahm, Philipp
Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis
title Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis
title_full Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis
title_fullStr Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis
title_full_unstemmed Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis
title_short Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis
title_sort fosfomycin for antibiotic prophylaxis in men undergoing a transrectal prostate biopsy: a systematic review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221023/
https://www.ncbi.nlm.nih.gov/pubmed/37241143
http://dx.doi.org/10.3390/medicina59050911
work_keys_str_mv AT guhuimo fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT gujinseok fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT chunghoseok fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT jungseungil fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT kwondongdeuk fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT kimmyungha fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT jungjaehung fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT hanmiah fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT kangseungji fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT hwangeuchang fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis
AT dahmphilipp fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis